Table 2 Figures and assumptions used for the calculations.

Proportion of practice population of 10,000

.056 [9]

.006 [10, 11]

Proportion eligible for treatment

ACE-I

.75

.75

BB

.75

.75

Aspirin

.90

N/a

Statins

.80

N/a

Spironolactone

N/a

.75

Proportion eligible for incremental treatment –

(proportion currently on treatment)

ACE-I

.27 (.48)

.16 (.59)

BB

.43 (.32)

.43 (.32)

Aspirin

.19 (.71)

N/a

Statins

.61 (.19)

N/a

Spironolactone

N/a

.55 (.20)

Baseline risk of death in the next year expressed

as a proportion

.09 [10]

.29 [10]

RRR from trials.

ACE-I

.16 [15]

.15 [3]

BB

.23 [16]

.21 [17]

Aspirin

.12 [4]

N/a

Statins

.21 [18]

N/a

Spironolactone

N/a

.30 [19]

Costs (from MIMS, 2001)

ACE-I (Ramipril 2.5 mg @ €7.51/28; Lisinopril 10 mg @9.70/28)

€100 per year

€100 per year

BB (Atenolol 25 mg @ €4.40/28; Metoprolol 100 mg @€6.68/56)

€45 per year

€45 per year

Spironolactone 100 mg @ €39.50/100

€144 per year

Aspirin @ 94p/28

€11 per year

Statins (Simvastatin 20 mg or Pravastatin 20 mg@ €29.69/28)

€386 per year